Privately-held AI diagnostics company IDx announced earlier this month that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo request to market IDx-DR. IDx-DR is an AI-based diagnostic system for the autonomous detection of diabetic retinopathy, a leading cause of blindness. More than 30 million Americans have diabetes, and an estimated…